| Title |
Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis
|
|---|---|
| Published in |
Neurotherapeutics, October 2017
|
| DOI | 10.1007/s13311-017-0557-4 |
| Pubmed ID | |
| Authors |
Jeffrey M Gelfand, Bruce A C Cree, Stephen L Hauser |
| Abstract |
Selective depletion of CD20(+) B cells by anti-CD20 monoclonal antibodies as monotherapy in multiple sclerosis (MS) profoundly suppresses acute inflammatory disease activity and signifies an important advance in the treatment of relapsing-remitting MS. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, is also the first proven therapy to lessen disability progression in primary progressive MS-a breakthrough for patients with a disease that had no proven therapy. Ocrelizumab is generally well tolerated, with the most common adverse events experienced being infusion reactions and infections. In ocrelizumab trials in MS a numerical imbalance in the risk of malignancies was observed. In this article, we review advances in anti-CD20 B-cell-depleting biological therapies for MS, including ocrelizumab, rituximab, and ofatumumab. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 248 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 248 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 31 | 13% |
| Researcher | 26 | 10% |
| Student > Ph. D. Student | 25 | 10% |
| Student > Master | 23 | 9% |
| Student > Doctoral Student | 20 | 8% |
| Other | 44 | 18% |
| Unknown | 79 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 72 | 29% |
| Neuroscience | 27 | 11% |
| Biochemistry, Genetics and Molecular Biology | 17 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 15 | 6% |
| Immunology and Microbiology | 8 | 3% |
| Other | 25 | 10% |
| Unknown | 84 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 October 2021.
All research outputs
#2,756,939
of 25,394,764 outputs
Outputs from Neurotherapeutics
#262
of 1,307 outputs
Outputs of similar age
#50,928
of 331,296 outputs
Outputs of similar age from Neurotherapeutics
#8
of 25 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,307 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 18.2. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 331,296 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 25 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.